Emergent BioSolutions (EBS) Capital Expenditures Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 75.58% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 28.56% |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn | -32.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.49% |
| Dec 31, 2025 | 86.58% |
| Sep 30, 2025 | -29.43% |
| Jun 30, 2025 | -55.13% |
| Mar 31, 2025 | -51.83% |
| Dec 31, 2024 | -56.03% |
| Sep 30, 2024 | 29.72% |
| Jun 30, 2024 | 157.76% |
| Mar 31, 2024 | -53.35% |
| Dec 31, 2023 | 85.38% |
| Sep 30, 2023 | 28.15% |
| Jun 30, 2023 | -17.37% |
| Mar 31, 2023 | -31.44% |
| Dec 31, 2022 | -29.08% |
| Sep 30, 2022 | 22.17% |
| Jun 30, 2022 | 4.17% |
| Mar 31, 2022 | 65.53% |
| Dec 31, 2021 | 36.56% |
| Sep 30, 2021 | -47.58% |
| Jun 30, 2021 | -27.22% |